SynthesisEuropean eating disorders review : the journal of the Eating Disorders Association2026
Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta-Analysis.
Synthesis in European eating disorders review : the journal of the Eating Disorders Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta-Analysis.European eating disorders review : the journal of the Eating Disorders Association · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the efficacy and safety of lisdexamfetamine, topiramate, and naltrexone/bupropion for treating binge eating disorder (BED) using network meta-analysis.
methodWe systematically searched PubMed, Scopus, ClinicalTrials.gov, and Cochrane Central up to February 2025 for randomized controlled trials evaluating these medications versus placebo in adults with BED. Primary outcomes were changes in binge eating frequency and body weight; secondary outcomes included serious adverse events, discontinuation rates, and common side effects. A frequentist random-effects network meta-analysis was performed.
resultsTwelve trials (n = 1988) met inclusion criteria. Both lisdexamfetamine (MD -1.61, 95% CI: -2.41 to -0.81) and topiramate (MD -1.63, 95% CI: -2.53 to -0.74) significantly reduced binge eating frequency versus placebo, with comparable efficacy. Topiramate produced the greatest weight loss (MD -5.5 kg), followed by lisdexamfetamine (-4.6 kg). Naltrexone/bupropion did not significantly reduce binge frequency (MD -2.07, 95% CI: -4.45 to 0.31). Lisdexamfetamine was associated with higher risks of dry mouth and gastrointestinal events. No significant increase in serious adverse events was observed for any medication.
conclusionsTopiramate and lisdexamfetamine are effective for reducing binge episodes and weight in BED. Naltrexone/bupropion showed modest weight effects but lacked clear efficacy for binge reduction. These findings support topiramate and lisdexamfetamine as primary pharmacologic options for BED.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.